July 30, 2008 -
Eisai Co., Ltd. (Headquarters: Tokyo, President & CEO: Haruo Naito) announced that Eisai China Inc. (Headquarters: Suzhou, President: Yukio Akada, “ECI”), a wholly-owned subsidiary of Eisai Co., Ltd., has entered into license agreement with
Health Vision Enterprise Ltd. (Headquarters: Hong Kong, Directors: Alex Leung and Zona Yim, “Health Vision”), a sales subsidiary of
STADA Arzneimittel AG (Headquarters: Germany, “STADA”), for sales and repack of
-
Lipon 300 STADA® (generic name:
-lipoic acid) in China.
-
Lipon 300 STADA® is a treatment for diabetic neuropathic pain developed by STADA.
With this agreement, ECI will take over sales promotion activities for
-
Lipon 300 STADA® in China from Health Vision from August 1. In addition, ECI will prepare for filing an application for repacking the product at its Suzhou plant. Upon approval, ECI will assume repacking and sales of
-
Lipon 300 STADA® in China.
-
Lipon 300 STADA® is a therapeutic agent for diabetic neuropathic pains developed by
STADA, and has been on the market in China since 2005. It relieves neuropathic pain associated with diabetes by its antioxidant effect, which reduces overproduction of oxygen species and normalization of glucose metabolism...
Eisai's Press Release -
July 30, 2008 - Eisai Co., Ltd. (Headquarters: Tokyo, President & CEO: Haruo Naito) announced that Eisai China Inc. (Headquarters: Suzhou, President: Yukio Akada, “ECI”), a wholly-owned subsidiary of Eisai Co., Ltd., has entered into license agreement with Health Vision Enterprise Ltd. (Headquarters: Hong Kong, Directors: Alex Leung and Zona Yim, “Health Vision”), a sales subsidiary of STADA Arzneimittel AG (Headquarters: Germany, “STADA”), for sales and repack of 
With this agreement, ECI will take over sales promotion activities for 
